Immunohistochemistry in the era of personalised medicine

Journal of Clinical Pathology

Volumn 66, Issue 1, 2013, Pages 58-61

  McCourt, Clare Margaret ^a   Boyle, David ^a   James, Jacqueline ^a   Salto Tellez, Manuel ^a,b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; CETUXIMAB; CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTROGEN RECEPTOR; GEFITINIB; K RAS PROTEIN; PROGESTERONE RECEPTOR; PROSTATE SPECIFIC ANTIGEN; PROTEIN S 100; SMOOTH MUSCLE ACTIN; TAMOXIFEN; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; COLORECTAL CANCER; DIAGNOSTIC VALUE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MISMATCH REPAIR; PERSONALIZED MEDICINE; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INDIVIDUALIZED MEDICINE; LABORATORIES, HOSPITAL; LUNG NEOPLASMS; PATHOLOGY, MOLECULAR; PATHOLOGY, SURGICAL; RECEPTOR, ERBB-2; RECEPTORS, STEROID; TUMOR MARKERS, BIOLOGICAL;

EID: 84871924245     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2012-201140     Document Type: Article

References (44)

1. Coons AH, Creech HJ, Jones RN. Immuno-logical properties of an antibody containing a fluorescent group. Proc Sot Exp Biol Med 1941;47:200-2.
2. Stemberger LA. Immunocytochemistry. New York: Wiley, 1979:130-69.
3. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol 2000;13:962-72.
4. Coindre JM. Immunohistochemistry in the diagnosis of soft tissue tumours. Histopathology 2003;43:1-16. (Pubitemid 36836582)
5. Barak V, Goike H, Panaretakis KW, et al. Clinical utility of cytokeratins as tumor markers. Clin Biochem 2004;37:529-40. (Pubitemid 38845016)
6. Lane EB, Alexander CM. Use of keratin antibodies in tumor diagnosis. Semin Cancer Biol 1990;1:165-79.
7. Chu PG, Weiss LM. Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases. Mod Pathol 2002;15:6-10. (Pubitemid 34081453)
8. Schmitt FC, Bacchi CE. S-100 protein: is it useful as a tumour marker in diagnostic immunocytochemistry? Histopathology 1989;15:281-8. (Pubitemid 19232651)
9. Weiss SW, Langloss JM, Enzinger FM. Value of S-100 protein in the diagnosis of soft tissue tumors with particular reference to benign and malignant Schwann cell tumors. Lab Invest 1983;49:299-308. (Pubitemid 13012059)
10. Springall DR, Gu J, Cocchia D, et al. The value of S-100 immunostaining as a diagnostic tool in human malignant melanomas. A comparative study using S-100 and neuron-specific enolase antibodies. Virchows Arch A Pathol Anat Histopathol 1983;400:331-43.
11. Dim DC, Cooley LD, Miranda RN. Clear cell sarcoma of tendons and aponeuroses: a review. Arch Pathol Lab Med 2007;131:152-6. (Pubitemid 46174153)
12. Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;61:8118-21. (Pubitemid 33091601)
13. Riegman PH, Vlietstra RJ, van der Korput JA, et al. Characterization of the prostate-specific antigen gene: a novel human kallikrein-like gene. Biochem Biophys Res Commun 1989;159:95-102. (Pubitemid 19087618)
14. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 1985;76:1899-903. (Pubitemid 16196061)
15. Higgins RA, Blankenship JE, Kinney MC. Application of immunohistochemistry in the diagnosis of non-Hodgkin and Hodgkin lymphoma. Arch Pathol Lab Med 2008;132:441-61. (Pubitemid 351328816)
16. Cho RJ, McCalmont TH, Ai WZ, et al. Use of an expanded immunohistochemical panel to distinguish cutaneous Hodgkin lymphoma from histopathologic imitators. J Cutan Pathol 2012;39:651-8. doi: 10.1111/j.1600-0560.2012.01872.
17. Vasen HF. Clinical description of the Lynch syndrome hereditary nonpolyposis colorectal cancer (HNPCC). Fam Cancer 2005;4:219-25. (Pubitemid 41242190)
18. Poulogiannis G, Frayling IM, Arends MJ. DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome. Histopathology 2010;56:167-79.
19. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004;96:261-8. (Pubitemid 38256271)
20. Salto-Tellez M, Lee SC, Chiu LL, et al. Microsatellite instability in colorectal cancer: considerations for molecular diagnosis and high-throughput screening of archival tissues. Clin Chem 2004;50:1082-6. (Pubitemid 38725805)
21. Hahnel R, Woodings T, Vivian AB. Prognostic value of estrogen receptors in primary breast cancer. Cancer 1979;44:671-5. (Pubitemid 10220153)
22. Bardou VJ, Arpino G, Elledge RM, et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003;21:1973-9. (Pubitemid 46606386)
23. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155-68. (Pubitemid 28144151)
24. Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 2008;21:S8-15.
25. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12. (Pubitemid 19147683)
26. Tandon AK, Clark GM, Chamness GC, et al. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989;7:1120-8. (Pubitemid 19196537)
27. De Laurentiis M, Arpino G, Massarelli E, et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 2005;11:4741-8. (Pubitemid 41557193)
28. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26. (Pubitemid 34111379)
29. Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 2001;28:13-29.
30. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97.
31. Salto-Tellez M, Yau EX, Yan B, et al. Where and by whom should gastric cancer HER2/neu status be assessed?: lessons from breast cancer. Arch Pathol Lab Med 2011;135:693-5.
32. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39. (Pubitemid 38637993)
33. Brevet M, Arcila M, Ladanyi M. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn 2010;12:169-76.
34. Sasaki H, Endo K, Yukiue H, et al. Mutation of epidermal growth factor receptor gene in adenosquamous carcinoma of the lung. Lung Cancer 2007;55:129-30. (Pubitemid 46038873)
35. Kang SM, Kang HJ, Shin JH, et al. Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung. Cancer 2007;109:581-7. (Pubitemid 46190967)
36. Ladanyi M, Pao W. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol 2008;21:S16-22. (Pubitemid 351592769)
37. Saltz LB, Meropol NJ, Loehrer PJS, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-8. (Pubitemid 41079832)
38. Chu E. Cetuximab targeted therapy: a new treatment paradigm for advanced colorectal cancer. Clin Colorectal Cancer 2004;3:205. (Pubitemid 38444305)
39. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23:1803-10. (Pubitemid 46211358)
40. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst 1998;90:675-684. (Pubitemid 28222141)
41. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-5.
42. Pirker R, Pereira JR, von Pawel J, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012;13:33-42.
43. O'Byrne KJ, Gatzemeier U, Bondarenko I, et al. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol 2011;12:795-805.
44. Markman M, Windle ML, Buehler B. Genetics of non-small-cell lung cancer. Medscape 2011. http://emedicine.medscape.com/article/1689988-overview